Alercell said on Wednesday that it is preparing a January launch for Lena Q51, a leukemia diagnostic test that uses DNA sequencing to test for 51 gene mutations.

Guangzhou MyGene Medical Technology Co., Ltd. announced the completion of several hundred million yuan in Series C financing. This round of financing was led by Efung Capital, the funds will be used for R&D and product registration for the IVD products.

Addition of next generation sequencing research panels, bioinformatics, positions IDT to become a leading oncology research solutions provider

Foundation Medicine said Wednesday its FoundationOne Liquid CDx test has been approved by the US Food and Drug Administration as a companion diagnostic for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).

Precision Medicine Asia and the National Cancer Center Hospital East in Japan are building a lung cancer clinicopathological genomic database and screening infrastructure that spans seven countries in the Asia-Pacific region, the groups said Wednesday.

Chinese cancer diagnostics firm SeekIn said Monday that it has received the CE mark for its PanCanSeek Cancer Mutation Detection Kit and now intends to market the test in the European Union and other regions that recognize the designation.

Cofactor Genomics on Wednesday announced the commencement of a study of its OncoPrism assay in non-small cell lung cancer (NSCLC).

A team from Stanford University, Columbia University, the New York Genome Center, and elsewhere has uncovered somatic tandem repeat expansions in tumors from a wide range of cancer types, including a potentially targetable repeat expansion in a subset of kidney cancers.

Bioinformatics company Envisagenics said Tuesday that it has formed a research collaboration with Queen Mary University of London and the technology-transfer arm of Cancer Research UK to explore the role of "alternative" splicing in hematopoietic cancer.

Agilent Technologies and Qiagen said on Monday and Tuesday respectively that they have gained US Food and Drug Administration approval of companion diagnostic assays for use with a new treatment for patients with advanced non-small cell lung cancer.